CN102846750B - Fengtongning composite preparation and preparation method thereof - Google Patents
Fengtongning composite preparation and preparation method thereof Download PDFInfo
- Publication number
- CN102846750B CN102846750B CN201210325217.0A CN201210325217A CN102846750B CN 102846750 B CN102846750 B CN 102846750B CN 201210325217 A CN201210325217 A CN 201210325217A CN 102846750 B CN102846750 B CN 102846750B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- vitamin
- grams
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000002131 composite material Substances 0.000 title abstract 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 9
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 9
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 9
- 229960001193 diclofenac sodium Drugs 0.000 claims abstract description 7
- 229960002702 piroxicam Drugs 0.000 claims abstract description 7
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims abstract description 7
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 6
- 229960003495 thiamine Drugs 0.000 claims abstract description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 23
- 241000903946 Clematidis Species 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000011837 pasties Nutrition 0.000 claims description 5
- 235000015424 sodium Nutrition 0.000 claims description 5
- 241000545442 Radix Species 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- -1 oryzanol Chemical compound 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 abstract description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 201000005569 Gout Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 206010018634 Gouty Arthritis Diseases 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 210000000988 bone and bone Anatomy 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 4
- 208000000112 Myalgia Diseases 0.000 abstract description 3
- 230000036592 analgesia Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 2
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 2
- 241000227129 Aconitum Species 0.000 abstract 1
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 235000007070 Angelica archangelica Nutrition 0.000 abstract 1
- 240000007087 Apium graveolens Species 0.000 abstract 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 abstract 1
- 206010006002 Bone pain Diseases 0.000 abstract 1
- 241000601164 Clematis orientalis Species 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 241000569285 Sabia japonica Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 235000015398 thunder god vine Nutrition 0.000 abstract 1
- 235000003786 wild celery Nutrition 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 208000006820 Arthralgia Diseases 0.000 description 18
- 201000003068 rheumatic fever Diseases 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000000552 rheumatic effect Effects 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 4
- 208000002894 beriberi Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 108091006515 Anion channels Proteins 0.000 description 1
- 102000037829 Anion channels Human genes 0.000 description 1
- 241000238008 Cerithidea rhizophorarum Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 102100033717 Retroviral-like aspartic protease 1 Human genes 0.000 description 1
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 1
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 1
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 1
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 1
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 1
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Fengtongning composite preparation and a preparation method thereof. The composite preparation is prepared from the following raw medicines, by weight, 6-12 parts of thunder god vine, 8-20 parts of sabia japonica maxim, 7-15 parts of incised notopterygium rhizome and root, 6-12 parts of wild celery, 3-10 parts of rheum, 6-12 parts of common monkshood mother-root, 5-10 parts of angelica archang lica, 7-15 parts of kusnezoff monkshood mother-root, 7-15 parts of angelica, 8-20 parts of Chinese clematis root and rhizome, 8-15 parts of piroxicam, 10-20 parts of diclofenac sodium, 7-15 parts of oryzanol, 8-18 parts of vitamin B1, and 6-12 parts of vitamin B6. The composite preparation has effects of rheumatism removing, blood circulation activating, blood stasis dissipating, meridian passage dredging, swelling subsiding and analgesia, and provides significant treatment effects for bone and muscle pain, gouty arthritis, rheumatism, rheumatoid arthritis, osteoarthritis and the like, wherein the total efficiency is 97.35%.
Description
Technical field
The invention belongs to field of medicaments, be specially a kind of bones and muscles pain that is used for the treatment of, gouty arthritis, the FENGTONGNING compound formulation of rheumatism, rheumatoid arthritis, osteoarthritis etc.
Background technology
The arthritis general reference occurs in the inflammatory diseases of human synovial and surrounding tissue thereof, can be divided into tens of kinds.The arthritic of China has more than 100,000,000, and number is in continuous increase.Clinical manifestation be joint red, swollen, hot, bitterly, dysfunction and joint deformity, severe patient cause joint disabled, affect patients ' life quality.Clinical common arthritis mainly comprises following several: rheumatoid arthritis, osteoarthritis, gouty arthritis etc.
The medicine of rheumatoid arthritis mainly comprises non-steroidal antiinflammatory drugs (NSAIDs), glucocorticoid (Gs), improve the state of an illness acts on antirheumatic (DMARDs), plant amedica, biological preparation etc. slowly.Non-steroidal antiinflammatory drugs is a line antirheumatic, can alleviate rapidly the joint symptom, but can not stop progression of disease, needs to take the circumstances into consideration the coupling other drug and share.Gs is the strongest anti-inflammatory drug, if correct, uses, and the reduction of patient inflammation, control the state of an illness, but can not abuse rapidly, is applicable to exist extra-articular manifestation, transition treatment and topical application.For rheumatoid arthritis patients, early stage, associating, individuation scheme are used DMARDs can control in early days pathological changes, obviously slow down disease progression, improve prognosis.This type of drug main will comprise methotrexate (MTX), sulfasalazine (SASP), leflunomide (LEF), hydroxychloroquine sulfate (HCQ) etc.The treatment of osteoarthritis, also can be at local joint application hyaluronic acid except the pain relieving (acetaminophen, NSAIDs) of suiting the medicine to the illness.Glucosamine class medicine and diacerein can delay progression of disease in the treatment of osteoarthritis, the suggestion prolonged application.The treatment of gouty arthritis comprises the anti-inflammatory analgesic (NSAIDs first-selection) of acute stage, and the treatment of paracmastic uric acid resisting.Should be according to the renal function of patients situation, have or not renal calculus etc. to select concrete medication.The uric acid resisting drug main will comprise and suppress uricopoiesis class (allopurinol) and promote urate excretion class (benzbromarone).Usually with headed by the latter, select.
Summary of the invention
The purpose of this invention is to provide a kind of compound formulation and be used for the treatment of bones and muscles pain, gouty arthritis, rheumatism, rheumatoid arthritis, osteoarthritis etc.
FENGTONGNING compound formulation of the present invention; Crude drug by following parts by weight: 6～12 parts of 6～12 parts of Radix Tripterygii Wilfordiis, 8～20 parts of Caulis Sinomenii, 7～15 parts of Rhizoma Et Radix Notopterygiis, 6～12 parts of Radix Angelicae Pubescentiss, 3～10 parts of Radix Et Rhizoma Rhei, 6～12 parts of Radix Aconitis, 5～10 parts of the Radixs Angelicae Dahuricae, 7～15 parts of Radix Aconiti Kusnezoffii, 7～15 parts of Radix Angelicae Sinensis, 8～20 parts of Radix Clematidis, 8～15 parts of piroxicams, 10～20 parts of diclofenac sodiums, 7～15 parts of oryzanol, 8～18 parts of vitamin B1s, vitamin B6 are made.
Can be by the crude drug of following parts by weight as optimizing also: 9 parts of 9 parts of Radix Tripterygii Wilfordiis, 15 parts of Caulis Sinomenii, 10 parts of Rhizoma Et Radix Notopterygiis, 9 parts of Radix Angelicae Pubescentiss, 7 parts of Radix Et Rhizoma Rhei, 9 parts of Radix Aconitis, 7 parts of the Radixs Angelicae Dahuricae, 10 parts of Radix Aconiti Kusnezoffii, 10 parts of Radix Angelicae Sinensis, 16 parts of Radix Clematidis, 12 parts of piroxicams, 15 parts of diclofenac sodiums, 12 parts of oryzanol, 12 parts of vitamin B1s, vitamin B6 be made.
The preparation method of this compound formulation comprises the following steps:
A, by Radix Tripterygii Wilfordii, Caulis Sinomenii, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Radix Et Rhizoma Rhei, Radix Aconiti, the Radix Angelicae Dahuricae, Radix Aconiti Kusnezoffii, Radix Angelicae Sinensis according to warm water bubble 3～12 hours for described parts by weight mix homogeneously;
B, the mixture in step a heating is brewed into to pasty state;
C, to the Radix Clematidis powder that adds described parts by weight in the mixture in step b;
D, grind to form powdery after will the mixture in step c drying;
E, to mix homogeneously after the piroxicam that adds described parts by weight in the mixture in steps d, diclofenac sodium, oryzanol, vitamin B1, vitamin B6 powder.
By the medicated powder of mix homogeneously, in incapsulating according to every 0.62 gram, each serving with 1～2, every day 1～2 time.
In compound formulation prescription of the present invention, Radix Tripterygii Wilfordii is dispeled the wind, removing toxic substances, and parasite killing, the external treating rheumatic arthritis, skin is itched, and kills maggot, wriggler, water-snail eradication, malicious Mus; The Caulis Sinomenii expelling wind and removing dampness, promoting blood circulation and detoxication, cure mainly rheumatic arthralgia, the arthroncus of knee, edema, beriberi, treating swelling and pain by traumatic injury, fracture, deep abscess, osteomyelitis, suppurative arthritis, spondylitis, sore swollen toxin, skin pruritus; The Rhizoma Et Radix Notopterygii exterior cold of faling apart, wind-damp dispelling, sharp joint, pain relieving, main affection of exogenous wind-cold, have a headache lossless, mimeograph cold-damp numbness, edema due to wind pathogen edema, sore swollen toxin; The Radix Angelicae Pubescentis expelling wind and dampness; Dispersing cold for relieving pain, for anemofrigid-damp arthralgia, lumbocrural pain, few cloudy volt wind headache, headache toothache; The Radix Et Rhizoma Rhei purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation, for the excess-heat constipation, stagnant stomachache, dysentery is not well, jaundice due to damp-heat, heat in blood is told nosebleed, conjunctival congestion, pharyngeal swelling, abdominalgia with intestinal abscess, carbuncle furuncle, blood stasis amenorrhea, traumatic injury, external treatment burn due to hot liquid or fire; Upper gastrointestinal hemorrhage; The Radix Aconiti expelling wind and removing dampness, antalgic, have a pain for anemofrigid-damp arthralgia, arthralgia, trusted subordinate's cold type of pain, colic of cold type; Radix Angelicae Dahuricae wind-damp dispelling, the evacuation of pus of invigorating blood circulation, the granulation promoting pain relieving, for headache, toothache, nasal sinusitis, hemorrhoidal hamorrhage anal fistula, leucorrhea with red and white discharge, ulcer sores, skin pruritus; Radix Aconiti Kusnezoffii is searched wind prevailing over dampness, and dispersing cold for relieving pain is opened expectorant, and detumescence, control anemofrigid-damp arthralgia, paralysis due to windstroke, tetanus, wind syndrome of head, coldness and pain in the epigastrium, accumulation of phlegm in the hypochondrium, air parcel, cold-dysentery, sore throat, carbuncle, furuncle, scrofula; Chinese angelica blood supplementing is invigorated blood circulation, menstruction regulating and pain relieving, and loosening bowel to relieve constipation, for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores; The Radix Clematidis expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, expectorant water, the loose hypochondriac lump, cure mainly gout insensitive impediment, rheumatic arthralgia, numb limbs and tense tendons, chills and pain of the waist and kness, the contracture of muscle arteries and veins, joint stuffiness, beriberi, malaria, lump in the abdomen, tetanus, tonsillitis, all a fishbone or other bone caught in the throat pharynxs.
Piroxicam is used for the treatment of rheumatic and rheumatoid arthritis, and obvious analgesia, antiinflammatory and certain detumescence effect are arranged; Diclofenac sodium is for alleviating rheumatoid arthritis, osteoarthritis.The acute attack stage of the various chronic arthritiss such as SpA, gouty arthritis, rheumatic arthritis or the arthralgia symptom of persistence; Oryzanol acts on autonomic nervous system and the secretion maincenter of diencephalon, thereby improves and the symptoms such as regulating plant maladjusted nervous system, incretion balance obstacle and psychataxia; It can cause vitamin B1 deficiency Vitamin B1 deficiency, also may relate to the adjusting of anion channel in nervous tissue, relevant with neuritis; The vitamin B6 Main Function is at the blood of human body, muscle, nerve, skin etc.The manufacture, fat that function has gastric acid in synthetic, the digestive system of antibody with protein utilization (especially should supplement when losing weight), maintain sodium/potassium balance (stablizing nervous system).
All medicine compatibilities, remove that rheumatism, blood circulation promoting and blood stasis dispelling, dysmenorrhea are active, reducing swelling and alleviating pain; The treatment bones and muscles pain, gouty arthritis, rheumatism, rheumatoid arthritis, osteoarthritis texts are remarkable.
Relevant clinical data is as follows: in 1547 observed examples, and male 722 examples (46.64%), female's 825 examples (53.36%); At minimum 16 years old of age, maximum 76 years old, wherein the course of disease was the longest 40 years, the shortest 1 month.In 1547 examples of observing, cold rheumatoid joint pain 413 examples (26.7%), rheumatic arthritis 412 examples (26.6%), rheumatoid arthritis 360 examples (23.3%), osteoarthritis 362 examples (23.4%).
Diagnosis basis: the rheumatism diagnostic criteria that rheumatic arthritis and rheumatoid arthritis are ordered with reference to national combination of Chinese and Western medicine association core is foundation, bone matrix hyperplasia is shown in the inspection of osteoarthritis Main Basis x-ray, and the arthroncus of cold rheumatoid joint pain Main Basis, pain, limitation of activity comprehensively judge.Rheumatic arthralgia or joint symmetry swell and ache repeatedly, and limitation of activity is observation index.Cold rheumatoid joint pain and osteoarthritis cause acute attack because of tired, diseases caused by exogenous pathogenic factor cold-damp, knee joint swelling, and the pain increased, and limitation of activity is observation index.
Therapeutic Method: in incapsulating according to every 0.62 gram, each oral 1～2, every day 1～2 time.
Efficacy evaluation: cure: the joint of getting involved after cold rheumatoid joint pain and Human Osteoarthritis treatment, myalgia disappears, and joint function recovery is normal, and erythrocyte sedimentation rate fast person be down to normally.Rheumatic arthritis and the patient with rheumatoid arthritis various arthralgia of getting involved after treatment disappear, and joint function recovery is normal, and check ESR, ASO, tri-indexs of RF recover normal.Produce effects: cold rheumatoid joint pain and Human Osteoarthritis are after treatment, and large of the joint of getting involved, myalgia disappear or obviously alleviate, or the fast person of erythrocyte sedimentation rate recovered normally, and arthralgia disappears not yet fully.The arthroncus of getting involved after treatment of rheumatic arthritis, patient with rheumatoid arthritis is clearly better or disappears, and check ESR, ASO, RF have binomial to recover normal person.Effectively: after 1 course of therapy, the arthralgia of getting involved or the person of taking a favorable turn that swells and ache.Invalid: after 1 course of therapy, the arthralgia of getting involved or the nothing person of being clearly better that swells and ache.
After the case treatment, curative effect statistical result is as follows:
The specific embodiment
The invention will be further described for embodiment plan given below; but can not be interpreted as it is limiting the scope of the invention; according to the present invention, content, to nonessential improvement and adjustment more of the present invention, still belongs to protection scope of the present invention to those skilled in the art.
Embodiment 1: get Radix Tripterygii Wilfordii 90 grams, Caulis Sinomenii 150 grams, Rhizoma Et Radix Notopterygii 100 grams, Radix Angelicae Pubescentis 90 grams, Radix Et Rhizoma Rhei 70 grams, Radix Aconiti 90 grams, the Radix Angelicae Dahuricae 70 grams, Radix Aconiti Kusnezoffii 70 grams, Radix Angelicae Sinensis 100 grams and mix with warm water bubble 8 hours; Then heat it is brewed into to pasty state; The Radix Clematidis powder that adds 160 grams; Grind to form powdery after oven dry; Add mix homogeneously after piroxicam powder 120 grams, diclofenac sodium powder 150 grams, oryzanol powder 120 grams, vitamin B1 powder 120 grams, vitamin B6 powder 90 grams.In incapsulating according to every 0.62 gram, each serving with 1～2, every day 1～2 time.
Embodiment 2: get Radix Tripterygii Wilfordii 60 grams, Caulis Sinomenii 80 grams, Rhizoma Et Radix Notopterygii 70 grams, Radix Angelicae Pubescentis 60 grams, Radix Et Rhizoma Rhei 30 grams, Radix Aconiti 60 grams, the Radix Angelicae Dahuricae 50 grams, Radix Aconiti Kusnezoffii 100 grams, Radix Angelicae Sinensis 70 grams and mix with warm water bubble 3 hours; Then heat it is brewed into to pasty state; The Radix Clematidis powder that adds 800 grams; Grind to form powdery after oven dry; Add mix homogeneously after piroxicam powder 80 grams, diclofenac sodium powder 100 grams, oryzanol powder 7 grams, vitamin B1 powder 80 grams, vitamin B6 powder 60 grams.In incapsulating according to every 0.62 gram, each serving with 1～2, every day 1～2 time.
Embodiment 3: get Radix Tripterygii Wilfordii 120 grams, Caulis Sinomenii 200 grams, Rhizoma Et Radix Notopterygii 150 grams, Radix Angelicae Pubescentis 120 grams, Radix Et Rhizoma Rhei 100 grams, Radix Aconiti 120 grams, the Radix Angelicae Dahuricae 100 grams, Radix Aconiti Kusnezoffii 150 grams, Radix Angelicae Sinensis 150 grams and mix with warm water bubble 12 hours; Then heat it is brewed into to pasty state; The Radix Clematidis powder that adds 200 grams; Grind to form powdery after oven dry; Add mix homogeneously after piroxicam powder 150 grams, diclofenac sodium powder 200 grams, oryzanol powder 150 grams, vitamin B1 powder 180 grams, vitamin B6 powder 120 grams.In incapsulating according to every 0.62 gram, each serving with 1～2, every day 1～2 time.
Claims (3)
1. a FENGTONGNING compound formulation; It is characterized in that being made by the crude drug of following parts by weight: 6～12 parts of Radix Tripterygii Wilfordiis, 8～20 parts of Caulis Sinomenii, 7～15 parts of Rhizoma Et Radix Notopterygiis, 6～12 parts of Radix Angelicae Pubescentiss, 3～10 parts of Radix Et Rhizoma Rhei, 6～12 parts of Radix Aconitis, 5～10 parts of the Radixs Angelicae Dahuricae, 7～15 parts of Radix Aconiti Kusnezoffii, 7～15 parts of Radix Angelicae Sinensis, 8～20 parts of Radix Clematidis, 8～15 parts of piroxicams, 10～20 parts of diclofenac sodiums, 7～15 parts of oryzanol, 8～18 parts of vitamin B1s, 6～12 parts of vitamin Bies.
2. compound formulation according to claim 1, it is characterized in that being made by the crude drug of following parts by weight: 9 parts of Radix Tripterygii Wilfordiis, 15 parts of Caulis Sinomenii, 10 parts of Rhizoma Et Radix Notopterygiis, 9 parts of Radix Angelicae Pubescentiss, 7 parts of Radix Et Rhizoma Rhei, 9 parts of Radix Aconitis, 7 parts of the Radixs Angelicae Dahuricae, 10 parts of Radix Aconiti Kusnezoffii, 10 parts of Radix Angelicae Sinensis, 16 parts of Radix Clematidis, 12 parts of piroxicams, 15 parts of diclofenac sodiums, 12 parts of oryzanol, 12 parts of vitamin B1s, 9 parts of vitamin Bies.
3. a method for preparing the described compound formulation of claim 1 is characterized in that comprising the following steps:
A, by Radix Tripterygii Wilfordii, Caulis Sinomenii, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Radix Et Rhizoma Rhei, Radix Aconiti, the Radix Angelicae Dahuricae, Radix Aconiti Kusnezoffii, Radix Angelicae Sinensis according to warm water bubble 3～12 hours for described parts by weight mix homogeneously;
B, the mixture in step a heating is brewed into to pasty state;
C, to the Radix Clematidis powder that adds described parts by weight in the mixture in step b;
D, grind to form powdery after will the mixture in step c drying;
E, to mix homogeneously after the piroxicam that adds described parts by weight in the mixture in steps d, diclofenac sodium, oryzanol, vitamin B1, vitamin B6 powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210325217.0A CN102846750B (en) | 2012-09-06 | 2012-09-06 | Fengtongning composite preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210325217.0A CN102846750B (en) | 2012-09-06 | 2012-09-06 | Fengtongning composite preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102846750A CN102846750A (en) | 2013-01-02 |
| CN102846750B true CN102846750B (en) | 2014-01-08 |
Family
ID=47393995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210325217.0A Expired - Fee Related CN102846750B (en) | 2012-09-06 | 2012-09-06 | Fengtongning composite preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102846750B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105641586A (en) * | 2016-03-01 | 2016-06-08 | 杨长军 | Fengtongning preparation and preparation method thereof |
| CN110613817A (en) * | 2019-10-11 | 2019-12-27 | 文莉 | Pharmaceutical composition and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114165A (en) * | 2011-03-01 | 2011-07-06 | 徐海彬 | Plaster for treating pain of cervical and lumbar vertebrae and preparation method thereof |
-
2012
- 2012-09-06 CN CN201210325217.0A patent/CN102846750B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114165A (en) * | 2011-03-01 | 2011-07-06 | 徐海彬 | Plaster for treating pain of cervical and lumbar vertebrae and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102846750A (en) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102441081A (en) | Medicament for treating gout and its preparation method | |
| CN104189871A (en) | Medicated wine for treating osteoproliferation | |
| CN103211932A (en) | Traditional Chinese medicine composition for treating rheumatism | |
| CN103735927B (en) | A kind of Chinese medicine composition for the treatment of acute stage of gout and preparation method thereof | |
| CN102836307A (en) | Chinese herbal medicine formula for treating traumatic injuries, tendon injuries and fractures | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN103405653B (en) | External preparation for treating gouty arthritis | |
| CN102764360B (en) | Traditional Chinese medicine composition for treating acute cystitis | |
| CN103100003B (en) | Traditional Chinese medicine composition for treating acute gouty arthritis | |
| CN113209182B (en) | A Chinese medicinal composition for treating rheumatoid arthritis, and its preparation method | |
| CN104547936A (en) | Traditional Chinese medicine for treating local induration of vascular access of hemodialysis patient | |
| CN110876796B (en) | Traditional Chinese medicine composition for treating acute gout attack and preparation method and application thereof | |
| CN103908642B (en) | A kind of medicine treating cold rheumatoid joint pain and preparation method thereof | |
| CN102716381B (en) | Traditional Chinese medicine used for treating appendicitis | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN104173804A (en) | Traditional Chinese medicine for treating nephritis | |
| CN104147261A (en) | Traditional Chinese medicine preparation for treating rheumatic arthritis | |
| CN103405647A (en) | TCM composition for treating nephritis and kidney failure | |
| CN102671027B (en) | Traditional Chinese medicine for curing calculi in urinary system | |
| CN107233469A (en) | A kind of Chinese medicine of set a broken bone | |
| CN103933278A (en) | Preparation method of Tibetan drug for treating gout disease | |
| CN104491799B (en) | A kind of traditional Chinese powder medicine for application treatment rheumatoid arthritis | |
| CN104689235B (en) | A kind of Chinese medicine composition for treating women scapulohumeral periarthritis | |
| CN104491327A (en) | Spraying agent for treating bedsore | |
| CN104147576B (en) | A kind of external application medicated wine treating ischemic heart desease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140108 |